These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Retroperitoneal and Mesenteric Liposarcomas.
    Author: Siew CCH, Apte SS, Baia M, Gyorki DE, Ford S, van Houdt WJ.
    Journal: Surg Oncol Clin N Am; 2022 Jul; 31(3):399-417. PubMed ID: 35715141.
    Abstract:
    Retroperitoneal liposarcomas are a rare entity and are comprised mostly of the well-differentiated and dedifferentiated subtypes. Eight-year survival ranges from 30% to 80% depending on histologic subtype and grade. Surgery is the cornerstone of treatment and compartment resection is the current standard. Mesenteric liposarcomas are extremely rare and comprise more high-grade lesions, with poorer prognosis of 50% 5-year overall survival. They are managed with a similar aggressive surgical approach. This review presents the current management of retroperitoneal and mesenteric liposarcomas.
    [Abstract] [Full Text] [Related] [New Search]